PrediabetesG3NCT07477249
Continuous Glucose Monitoring (CGM) in Prediabetes With Community Based Recruitment
A study testing CGM in people with Prediabetes, run by David S Black, PhD at 1 site in United States.
Trial summary
The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. Read more about this study
- Who is it for?
- Ages 35 years and olderHealthy volunteers can take part
- Conditions the study is for
- Prediabetes
- What is being tested?
- CGM
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Feb 2026to 30 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 35 years of age or older
- Willingness to wear CGM sensor
- Prediabetes by finger prick blood A1C% or fasting glucose
- Centers for Disease Control and Prevention (CDC) prediabetes risk test score of 5 or higher or recent prediabetes diagnosis from physician
Who cannot join
- Diagnosed with any disorder that interferes with glucose
- Influential medical disorder/event affecting ability to participate in study
- Incompatible smartphone device not pairing with Dexcom G6 app
- Currently pregnant
- Previously participated in other Continuous Glucose Monitoring studies
- Having a planned trip outside California in the following 2 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ruth Flores contact
United States1 site, 1 recruiting
- Recruiting
Southern California Center for Latino Health (SCCLH)
Los Angeles, California, 90031
About this study
Official title: Continuous Glucose Monitoring (CGM) in Prediabetes With Health Education Videos
The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. The goal is to prevent transition to type 2 diabetes (T2D).
Read the detailed description
The primary objective of this new project is to enhance glycemic control in individuals with prediabetes and deter the progression to Type 2 Diabetes (T2D) within the Los Angeles (LA) County community. Our proposal involves conducting a Phase 0 intervention development study. This study will enlist a final sample of N=50 adults who speak English and/or Spanish, have non-clinical prediabetes, and test positive for prediabetes via a finger-prick A1c% screening. Participants will wear CGM devices for 20 days, with glucose data masked for the first 10 days and unmasked for the next 10 days. During the unmasked phase, participants will receive daily health education videos on their smartphones. The study will compare the duration of glucose excursions between the masked and unmasked phases to assess the impact of CGM feedback and health education on glucose regulation.
- Conditions
- Prediabetes
- Being tested
- CGM
- Keywords
- Prediabetes, Glucose control, Feedback, Health education, Artificial intelligence, Behavioral analysis
- Medical subject headings
- Prediabetic State, Health Education
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CGMDevice
The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.
| Study group | Role | What they receive |
|---|---|---|
| Single Group: CGM with Masked Phase A and Unmasked Phase B | Other | Participants wear a CGM on the back of the arm. During Phase A, glucose values are not visible to participants. During Phase B, glucose values are visible via the phone app. Receives: Device: CGM |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucose levels
Mean glucose in mg/dL
Measured: Maximum of 20 days of continuous wear
Secondary outcomes (1)
Time out of range > 140 mg/dL (TOR)
Time out of range > 140 mg/dL (TOR)
Measured: Maximum of 20 days of continuous wear
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start26 Feb 2026
- Primary completion30 Mar 2027 (estimated)
- Study completion30 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PrediabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Sequential
- Model description
- Phase A / Phase B (AB) sequential condition design with CGM automated continuous glucose recording with glucose level masked and unmasked phases.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- David S Black, PhD
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Responsible party
- Sponsor-investigator, David S Black, PhD, University of Southern California
- Investigators
- David S Black, PhD MPH, Principal investigator, University of Southern California Keck School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07477249
- Sponsor's protocol ID
- UP-23-01001(b)
- Other IDs
- 3P50MD017344-03S3
- Acronym
- G3
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: IPD sharing is set up with affiliate USC-Children's Hospital Los Angeles (CHLA) P50 Center universities and hospitals under a registered data use agreement (DUA). Data and protocol documentation will be posted on the Open Science Framework
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Continuous Glucose Monitoring (CGM) in Prediabetes With Health Education Videos
- ClinicalTrials.gov ID
- NCT07477249
- Acronym / sponsor ID
- G3 / UP-23-01001(b)
- Conditions
- Prediabetes
- Keywords
- Prediabetes, Glucose control, Feedback, Health education, Artificial intelligence, Behavioral analysis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- David S Black, PhDUniversity, hospital or other
- Collaborators
- National Institute on Minority Health and Health Disparities (NIMHD)
- Study start
- 26 Feb 2026 (actual)
- Primary completion
- 30 Mar 2027 (estimated)
- Study completion
- 30 Mar 2027 (estimated)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this project is to develop a behavioral intervention that combines wearable continuous glucose monitoring (CGM) with smartphone feedback and educational video clips generated by artificial intelligence (AI) software to improve glycemic control among individuals with pre-diabetes. The goal is to prevent transition to type 2 diabetes (T2D).
Detailed description
The primary objective of this new project is to enhance glycemic control in individuals with prediabetes and deter the progression to Type 2 Diabetes (T2D) within the Los Angeles (LA) County community. Our proposal involves conducting a Phase 0 intervention development study. This study will enlist a final sample of N=50 adults who speak English and/or Spanish, have non-clinical prediabetes, and test positive for prediabetes via a finger-prick A1c% screening. Participants will wear CGM devices for 20 days, with glucose data masked for the first 10 days and unmasked for the next 10 days. During the unmasked phase, participants will receive daily health education videos on their smartphones. The study will compare the duration of glucose excursions between the masked and unmasked phases to assess the impact of CGM feedback and health education on glucose regulation.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Phase A / Phase B (AB) sequential condition design with CGM automated continuous glucose recording with glucose level masked and unmasked phases.
| Arm | Type | Receives |
|---|---|---|
| Single Group: CGM with Masked Phase A and Unmasked Phase B | Other | Device: CGMParticipants wear a CGM on the back of the arm. During Phase A, glucose values are not visible to participants. During Phase B, glucose values are visible via the phone app. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- 35 years of age or older
- Willingness to wear CGM sensor
- Prediabetes by finger prick blood A1C% or fasting glucose
- Centers for Disease Control and Prevention (CDC) prediabetes risk test score of 5 or higher or recent prediabetes diagnosis from physician
Key exclusion criteria (6 listed)
- Diagnosed with any disorder that interferes with glucose
- Influential medical disorder/event affecting ability to participate in study
- Incompatible smartphone device not pairing with Dexcom G6 app
- Currently pregnant
- Previously participated in other Continuous Glucose Monitoring studies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CGMThe CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A. | Device | Single Group: CGM with Masked Phase A and Unmasked Phase B |
Primary outcome
Glucose levels
Time frame: Maximum of 20 days of continuous wear
Mean glucose in mg/dL
1 secondary outcome
Time out of range > 140 mg/dL (TOR)
Time frame: Maximum of 20 days of continuous wear
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Dexcom G CGM system specificationsLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. IPD sharing is set up with affiliate USC-Children's Hospital Los Angeles (CHLA) P50 Center universities and hospitals under a registered data use agreement (DUA). Data and protocol documentation will be posted on the Open Science Framework
Related trials for Prediabetes
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Overweight, Prediabetic State
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Recruiting
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
PreDiabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ruth Flores contact
David S Black, PhD MPH principal investigator
University of Southern California Keck School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CGM in people with Prediabetes, run by David S Black, PhD at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David S Black, PhD MPH (3234428223, davidbla@usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucose levels (time frame: Maximum of 20 days of continuous wear). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.